Related Experiment Video
Updated: Jun 16, 2025

Targeting Biofilm Associated Staphylococcus aureus Using Resazurin Based Drug-susceptibility Assay
Published on: May 5, 2016
Thiazine-derived compounds in inhibiting efflux pump in Staphylococcus aureus K2068, mepA gene expression, and
Priscilla R Freitas1, Ana C J de Araújo1, Isaac M Araújo1
1Department of Biological Chemistry, Universidade Regional do Cariri, Crato-CE, Brazil.
Abstract:
Staphylococcus aureus is a bacterium responsible for resistance to multiple drugs and the efflux system is widely studied among the resistance mechanisms developed by this species. The present study evaluates the inhibition of the MepA efflux pump by thiadiazine-derived compounds. For this purpose, thiadiazine-derived compounds (IJ-14 to IJ-20) were tested against S. aureus K2068 strains. Microdilution tests were initially conducted to assess the Minimum Inhibitory Concentration (MIC) of the compounds and their efflux pump inhibition activity. In addition, fluorimetry tests were performed using BrEt emission and tests were conducted to inhibit the expression of the mepA gene. This involved comparing the bacterial gene expression with the antibiotic alone to the gene expression after combining compounds (IJ-17 and IJ-20) with the antibiotic. Furthermore, membrane permeability assessment tests and in silico molecular docking tests were performed. It was observed that the IJ17 and IJ20 compounds exhibited direct activity against the tested strain. The IJ17 compound produced significant results in the gene inhibition tests, which was also evidenced through the membrane permeability alteration test. These findings suggest that thiadiazine-derived compounds have promising effects against one of the main resistance mechanisms, with the IJ17 compound presenting observable mechanisms of action.
Insights
Thiadiazine compounds were tested against Staphylococcus aureus efflux pumps. Compound IJ17 showed significant inhibition of the MepA efflux pump and altered bacterial membrane permeability, suggesting a new strategy against antibiotic resistance.
Area of Science:
- Microbiology
- Medicinal Chemistry
Background:
- Staphylococcus aureus exhibits multidrug resistance, with efflux pumps being a key mechanism.
- The MepA efflux pump is a significant contributor to antibiotic resistance in S. aureus.
Purpose of the Study:
- To evaluate the potential of thiadiazine-derived compounds in inhibiting the MepA efflux pump.
- To investigate the mechanism of action of these compounds against S. aureus.
Main Methods:
- Minimum Inhibitory Concentration (MIC) and efflux pump inhibition assays.
- Gene expression analysis of mepA, membrane permeability tests, and in silico molecular docking.
- Testing of thiadiazine compounds (IJ-14 to IJ-20) against S. aureus K2068.
Main Results:
- Compounds IJ17 and IJ20 demonstrated direct activity against S. aureus.
- IJ17 significantly inhibited mepA gene expression and altered membrane permeability.
- Molecular docking provided insights into the interaction of compounds with the efflux pump.
Conclusions:
- Thiadiazine-derived compounds, particularly IJ17, show promise in combating S. aureus multidrug resistance.
- IJ17 exhibits potential as an efflux pump inhibitor, offering a novel approach to overcome resistance mechanisms.
More Related Videos
07:50Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments
Published on: October 25, 2024
06:36Improved Enzyme Protection Assay to Study Staphylococcus aureus Internalization and Intracellular Efficacy of Antimicrobial Compounds
Published on: September 8, 2021